Andy Huang1, Kathleen Brennan, Ricardo Azziz. 1. Department of Obstetrics and Gynecology, the David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Abstract
OBJECTIVE: To determine the prevalence of elevated total and free T, and DHEAS, alone and in combination, in patients with polycystic ovary syndrome (PCOS). DESIGN: Cross-sectional analysis. SETTING: Tertiary care academic medical center. PATIENT(S): Seven hundred twenty patients diagnosed with PCOS according to the National Institutes of Health 1990 criteria. INTERVENTION(S): History, physical examination, and blood sampling. MAIN OUTCOME MEASURE(S): Hyperandrogenemia, defined as at least one androgen value above the 95th percentile of 98 healthy control women (i.e., total T >88 ng/dL, free T >0.75 ng/dL, and DHEAS >2,750 ng/mL). RESULT(S): A total of 716 subjects with PCOS were included. The overall prevalence of hyperandrogenemia in PCOS was 75.3%. Supranormal levels of free T were present in 57.6%, of total T in 33.0%, and of DHEAS in 32.7% of patients with PCOS. When assessing the prevalence of two abnormal values, the prevalence of simultaneously elevated androgens was lowest with total T and DHEAS (1.7%) and highest with total T and free T (20.4%). Altogether, simultaneous elevations in all three markers were found in 8.7% of subjects with PCOS. CONCLUSION(S): Approximately three-fourths of patients with PCOS diagnosed by the National Institutes of Health 1990 criteria have evidence of hyperandrogenemia; the single most predictive assay was the measurement of free T with approximately 60% of patients demonstrating supranormal levels. Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
OBJECTIVE: To determine the prevalence of elevated total and free T, and DHEAS, alone and in combination, in patients with polycystic ovary syndrome (PCOS). DESIGN: Cross-sectional analysis. SETTING: Tertiary care academic medical center. PATIENT(S): Seven hundred twenty patients diagnosed with PCOS according to the National Institutes of Health 1990 criteria. INTERVENTION(S): History, physical examination, and blood sampling. MAIN OUTCOME MEASURE(S): Hyperandrogenemia, defined as at least one androgen value above the 95th percentile of 98 healthy control women (i.e., total T >88 ng/dL, free T >0.75 ng/dL, and DHEAS >2,750 ng/mL). RESULT(S): A total of 716 subjects with PCOS were included. The overall prevalence of hyperandrogenemia in PCOS was 75.3%. Supranormal levels of free T were present in 57.6%, of total T in 33.0%, and of DHEAS in 32.7% of patients with PCOS. When assessing the prevalence of two abnormal values, the prevalence of simultaneously elevated androgens was lowest with total T and DHEAS (1.7%) and highest with total T and free T (20.4%). Altogether, simultaneous elevations in all three markers were found in 8.7% of subjects with PCOS. CONCLUSION(S): Approximately three-fourths of patients with PCOS diagnosed by the National Institutes of Health 1990 criteria have evidence of hyperandrogenemia; the single most predictive assay was the measurement of free T with approximately 60% of patients demonstrating supranormal levels. Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Authors: M Asunción; R M Calvo; J L San Millán; J Sancho; S Avila; H F Escobar-Morreale Journal: J Clin Endocrinol Metab Date: 2000-07 Impact factor: 5.958
Authors: E Diamanti-Kandarakis; C R Kouli; A T Bergiele; F A Filandra; T C Tsianateli; G G Spina; E D Zapanti; M I Bartzis Journal: J Clin Endocrinol Metab Date: 1999-11 Impact factor: 5.958
Authors: R Azziz; L A Sanchez; E S Knochenhauer; C Moran; J Lazenby; K C Stephens; K Taylor; L R Boots Journal: J Clin Endocrinol Metab Date: 2004-02 Impact factor: 5.958
Authors: Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro Journal: Endocr Rev Date: 2015-10 Impact factor: 19.871